Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort




psoriasis, psoriatic arthritis, cohort studies


Patients with psoriasis are at risk of developing psoriatic arthritis, which can lead to irreversible joint damage. However, a proportion of patients with psoriasis and concomitant psoriatic arthritis remain undiscovered in practice. The aims of this study were: to prospectively determine prevalence, characteristics, and disease burden of psoriatic arthritis in a psoriasis population; and to determine the prevalence and characteristics of patients with active psoriatic arthritis, who were not under rheumatological care. Patients with psoriasis were screened by a rheumatologist at the dermatology outpatient clinic for psoriatic arthritis. Patients with suspected active psoriatic arthritis who were not seeing a rheumatologist were referred to a rheumatologist for confirmation. The total prevalence of psoriatic arthritis in this observational, prospective cohort (n = 303) was 24%. Patients with psoriasis with concomitant psoriatic arthritis had longer duration of skin disease and more often a treatment history with systemic therapies. In this academic, specialized, setting, 2.3% of patients (n = 7), were not receiving rheumatological care despite having active psoriatic arthritis. These patients were characterized by a combination of low (perceived) disease burden and low yield of screening questionnaires, making it difficult for dermatologists to discover psoriatic arthritis in these patients. Thus, screening for more subtle active arthritis in patients with psoriasis in a dermatology setting could be improved.


Download data is not yet available.


Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond) 2017; 17: 65-70. DOI:

Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015; 386: 2489-2498. DOI:

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013; 69: 729-735. DOI:

Tillett W, Charlton R, Nightingale A, Snowball J, Green A, Smith C, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology (Oxford) 2017; 56: 2109-2113. DOI:

Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: 242-248. DOI:

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251-265. DOI:

Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009; 27: 469-474.

Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581-587. DOI:

Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009; 68: 497-501. DOI:

Tinazzi I, Adami S, Zanolin EM, Caimmi C, Confente S, Girolomoni G, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) 2012; 51: 2058-2063. DOI:

Audureau E, Roux F, Lons DD, Bagot M, Cantagrel A, Dernis E, et al. Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'. J Eur Acad Dermatol Venereol 2018; 32: 1950-1953. DOI:

Urruticoechea-Arana A, Benavent D, Leon F, Almodovar R, Belinchon I, de la Cueva P, et al. Psoriatic arthritis screening: a systematic literature review and experts' recommendations. PLoS One 2021; 16: e0248571. DOI:

Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736-740. DOI:

Mease PJ, Gladman DD, Helliwell P, Khraishi MM, Fuiman J, Bananis E, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2014; 71: 649-655. DOI:

van Hal TW, Van den Reek JM, Groenewoud HM, Pasch MC, Van den Hoogen FH, Wenink MH, et al. Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): protocol for a longitudinal observational study. JMIR Res Protoc 2021; 10: e31647. DOI:

Ogdie A, Shin DB, Love TJ, Gelfand JM. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology (Oxford) 2022; 61: 1877-1884. DOI:

Helliwell PS, Waxman R. Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). Ann Rheum Dis 2018; 77: 467-468. DOI:

Gossec L, de WM, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73: 1012-1019. DOI:

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. DOI:

Merola JF, Tian H, Patil D, Richardson C, Scott A, Chen YH, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol 2022; 86: 748-757. DOI:

van Muijen ME, van Hal TW, Groenewoud HMM, van den Reek J, de Jong E. The skin may clear but the arthritis won't disappear: focusing on concomitant and new-onset psoriatic arthritis in a daily practice cohort of psoriasis patients on biologic therapy. Psoriasis (Auckl) 2020; 10: 29-37. DOI:

Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang S, Shin D, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis 2022; 81: 80-86. DOI:

Mulder MLM, van Hal TW, van den Hoogen FHJ, de Jong E, Vriezekolk JE, Wenink MH. Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. Rheumatology (Oxford) 2021; 60: 3165-3175. DOI:

Mease PJ, Etzel CJ, Huster WJ, Armstrong AW, Muram TM, Lisse J, et al. Evaluation of changes in skin and joint outcomes and associated treatment changes in psoriatic arthritis (psa): experience from the Corrona PsA/SpA Registry. J Rheumatol 2021; 48: 376-384. DOI:

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957-970. DOI:

van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups. Acta Derm Venereol 2020; 100: adv00215. DOI:

van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180: 31-42. DOI:

Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005; 58: 595-602. DOI:

Puyraimond-Zemmour D, Etcheto A, Fautrel B, Balanescu A, de Wit M, Heiberg T, et al. Associations between five important domains of health and the patient acceptable symptom state in rheumatoid arthritis and psoriatic arthritis: a cross-sectional study of 977 patients. Arthritis Care Res (Hoboken) 2017; 69: 1504-1509. DOI:

Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686-691. DOI:

Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. DOI:

Klaassen KM, van de Kerkhof PC, Bastiaens MT, Plusje LG, Baran RL, Pasch MC. Scoring nail psoriasis. J Am Acad Dermatol 2014; 70: 1061-1066. DOI:

Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212. DOI:

Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013; 72: 986-991. DOI:

Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664. DOI:

Additional Files



How to Cite

van Hal, T. W., Mulder, M. L., Wenink, M. H., Pasch, M. C., van den Hoogen, F. H., van den Reek, J. M., & de Jong, E. M. (2022). Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort. Acta Dermato-Venereologica, 102, adv00768.